Trial Profile
A Randomized, Double-Blind, Placebo Controlled Proof of Concept Study of LY2300559 in Patients With Migraine.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2018
Price :
$35
*
At a glance
- Drugs LY 2300559 (Primary)
- Indications Migraine with aura; Migraine without aura
- Focus Therapeutic Use
- 29 Oct 2012 Actual end date changed from Mar 2012 to April 2012 as reported by ClinicalTrials.gov.
- 16 Jul 2012 Actual end date changed from April 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 16 Jul 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.